Skip to main content

BioSilta Collaborates with KTH Stockholm

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) — The KTH Royal Institute of Technology said today it will use screening technology from Finnish start-up BioSilta Oy for KTH's Human Protein Atlas project.

YouDoBio was also named as the distributor of BioSilta products in Sweden and Denmark.

Terms for neither deal were disclosed.

BioSilta's EnBase technology will be used to accelerate secondary screening of previously poor expressing candidates for the Human Protein Atlas project. In a statement, the two firms said they have been collaborating to optimize protein screening using microwell plates and BioSilta's enzymatic release media technology.

“By combining our knowledge we have been table to develop a very reliable screening method used to determine if a protein could be successfully expressed or not,” KTH professor and Director of Protein Science Sophia Hober said in a statement. KTH is based in Stockholm, Sweden.

“We see a great potential in the EnBase technology and hope other research groups also will find this product beneficial,” Hober added.

BioSilta is based in Oulu, Finland and uses enzymes and biocatalytic activity to advance cell culture technology.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.